Americans have saved more than $700 million on prescription medications through TrumpRx.gov and most-favored-nation pricing, according to new White House data obtained by FOX Business.

The website lists transparent prices for more than 800 brand-name and generic medications from the 17 largest pharmaceutical companies, making the program a central part of the administration’s push to lower prescription drug costs through direct price listings and negotiated pricing terms.

Praluent, a cholesterol medication, will be added to TrumpRx.gov on Friday. The drug is used to help reduce the risk of stroke and heart attack in patients.

Praluent was jointly developed by Regeneron Pharmaceuticals and Sanofi. Regeneron is responsible for distribution and sales in the United States, while Sanofi handles those responsibilities in the rest of the world.

Before being added under most-favored-nation pricing, Praluent had a retail price of $537 for a one-month supply. Its new price is $225 for a one-month supply, a 60% reduction.

"TrumpRx.gov is a historic game changer for American patients, and this innovative initiative reflects how President Trump hasn’t been afraid to think outside the box to lower prescription drug prices," White House spokesman Kush Desai said. "The addition of Praluent, a powerful cholesterol medication, is another win for TrumpRx, and the Trump administration remains focused on delivering even more savings for the American people."

Pharmaceutical companies that enter into the Trump administration's most-favored-nation pricing agreements and commit to expanding U.S. manufacturing can avoid future 100% tariffs on imported medications. That links the pricing program to a broader administration effort to pair lower drug prices with incentives for domestic pharmaceutical production.

The 100% tariffs on medications are scheduled to begin Aug. 1, 2028, and rise to 200% one year later.